A Phase 3 interventional study of Product DNN.63.18.040 and Tramal® in Acute Pain, sponsored by Ache Laboratorios Farmaceuticos S.A.. Not yet recruiting. Open to participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Ache Laboratorios Farmaceuticos S.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluates the safety and efficacy of DNN.63.18.040 compared with Tramal® for the treatment of moderate to severe pain.
1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.
This study's planned enrollment of 370 is above the median of 86 across 905 interventional studies indexed under Acute Pain.
Browse Acute Pain studies →Ache Laboratorios Farmaceuticos S.A. is the lead sponsor of 36 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Product DNN.63.18.040
Drug: Tramal®
One capsule four times daily for 3 days
One capsule four times daily for 3 days
Total Pain Relief Score (TOTPAR6)
Time-weighted sum of pain relief scores over the first 6 hours following the first dose. Pain relief is rated on a scale from 0 (no relief) to 4 (complete relief). TOTPAR6 ranges from 0 to 24, with higher scores indicating greater overall pain relief.
Time frame: 6 hours after first dose
No study locations are listed for this record.
Start is estimated for Oct 2026; primary completion for Mar 2027, 5 months later.
Of 29 industry-sponsored phase 3 interventional studies under Acute Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's planned 5 months is below that.
Counting every sponsor, half of 54 studies reached it within 14 months; a quarter within 7 and three quarters within 25.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ache Laboratorios Farmaceuticos S.A. →